Abstract
Group I metabotropic glutamate receptors mediate slow excitatory neurotransmission in the central nervous system and are critical to activity-dependent synaptic plasticity, a cellular substrate of learning and memory. Dysregulated receptor signaling is implicated in neuropsychiatric conditions ranging from neurodevelopmental to neurodegenerative disorders. Importantly, group I metabotropic glutamate receptor signaling functions can be modulated by interacting proteins that mediate receptor trafficking, expression and coupling efficiency to signaling effectors. These interactions afford cell- or pathway-specific modulation to fine-tune receptor function, thus representing a potential target for pharmacological interventions in pathological conditions.
Keywords: Amyloid-β, CaMKIIα, caveolin-1, homer, mGluR, norbin, PrPc, synaptic plasticity.
Graphical Abstract
Current Neuropharmacology
Title:Group I Metabotropic Glutamate Receptor Interacting Proteins: Fine-Tuning Receptor Functions in Health and Disease
Volume: 14 Issue: 5
Author(s): Magdalena Kalinowska and Anna Francesconi
Affiliation:
Keywords: Amyloid-β, CaMKIIα, caveolin-1, homer, mGluR, norbin, PrPc, synaptic plasticity.
Abstract: Group I metabotropic glutamate receptors mediate slow excitatory neurotransmission in the central nervous system and are critical to activity-dependent synaptic plasticity, a cellular substrate of learning and memory. Dysregulated receptor signaling is implicated in neuropsychiatric conditions ranging from neurodevelopmental to neurodegenerative disorders. Importantly, group I metabotropic glutamate receptor signaling functions can be modulated by interacting proteins that mediate receptor trafficking, expression and coupling efficiency to signaling effectors. These interactions afford cell- or pathway-specific modulation to fine-tune receptor function, thus representing a potential target for pharmacological interventions in pathological conditions.
Export Options
About this article
Cite this article as:
Kalinowska Magdalena and Francesconi Anna, Group I Metabotropic Glutamate Receptor Interacting Proteins: Fine-Tuning Receptor Functions in Health and Disease, Current Neuropharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570159X13666150515234434
DOI https://dx.doi.org/10.2174/1570159X13666150515234434 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial (Thematic Selection: Strategies of Current Drugs and Alternative Treatments for Neurodegenerative Diseases)
Current Neuropharmacology Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients
Current Alzheimer Research TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Patents Relating to Diagnostic Advances in Age Related Macular Degeneration (AMD)
Recent Patents on DNA & Gene Sequences Differential Retinal Protein Expressions During form Deprivation Myopia in Albino Guinea Pigs
Current Proteomics Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents
Current Organic Chemistry Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Preface
Central Nervous System Agents in Medicinal Chemistry Chemical Diversity of Grape Products, a Complex Blend of Bioactive Secondary Metabolites
The Natural Products Journal Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Mapping Chemical Space Using Molecular Descriptors and Chemical Genetics: Deacetylase Inhibitors
Combinatorial Chemistry & High Throughput Screening α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research The Regulatory Effects of Glutamine on Illness and Health
Protein & Peptide Letters Herbal and Holistic Solutions for Neurodegenerative and Depressive Disorders: Leads from Ayurveda
Current Pharmaceutical Design